Alzamend Neuro is trading at $1.47, up 10.53%, with no clear company-specific catalyst identified.
- It closed at $1.31 on October 1; its latest official press release, on September 16, announced it regained compliance with Nasdaq listing standards.
- Markets rose after September employment growth came in weaker than expected; the S&P 500 gained 0.68% and Nasdaq Composite gained 1.10%. This risk-on context may have contributed, but does not establish a specific cause for the stock’s gain.